Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.
Circulating tumor DNA
DNA methylation
Epigenetic biomarkers
Liquid biopsy
Primary central nervous system lymphoma
TAM-MSP
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
05 05 2021
05 05 2021
Historique:
received:
17
03
2021
accepted:
22
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Definitive diagnosis of primary central nervous system lymphoma (PCNSL) requires invasive surgical brain biopsy, causing treatment delays. In this paper, we identified and validated tumor-specific markers that can distinguish PCNSL from other CNS tumors in tissues. In a pilot study, we tested these newly identified markers in plasma. The Methylation Outlier Detector program was used to identify markers in TCGA dataset of 48 diffuse large B-cell lymphoma (DLBCL) and 656 glioblastomas and lower-grade gliomas. Eight methylated markers clearly distinguished DLBCL from gliomas. Marker performance was verified (ROC-AUC of ≥ 0.989) in samples from several GEO datasets (95 PCNSL; 2112 other primary CNS tumors of 11 types). Next, we developed a novel, efficient assay called Tailed Amplicon Multiplexed-Methylation-Specific PCR (TAM-MSP), which uses two of the methylation markers, cg0504 and SCG3 triplexed with ACTB. FFPE tissue sections (25 cases each) of PCNSL and eight types of other primary CNS tumors were analyzed using TAM-MSP. TAM-MSP distinguished PCNSL from the other primary CNS tumors with 100% accuracy (AUC = 1.00, 95% CI 0.95-1.00, P < 0.001). The TAM-MSP assay also detected as few as 5 copies of fully methylated plasma DNA spiked into 0.5 ml of healthy plasma. In a pilot study of plasma from 15 PCNSL, 5 other CNS tumors and 6 healthy individuals, methylation in cg0504 and SCG3 was detectable in 3/15 PCNSL samples (20%). The Methylation Outlier Detector program identified methylated markers that distinguish PCNSL from other CNS tumors with accuracy. The high level of accuracy achieved by these markers was validated in tissues by a novel method, TAM-MSP. These studies lay a strong foundation for a liquid biopsy-based test to detect PCNSL-specific circulating tumor DNA.
Sections du résumé
BACKGROUND
Definitive diagnosis of primary central nervous system lymphoma (PCNSL) requires invasive surgical brain biopsy, causing treatment delays. In this paper, we identified and validated tumor-specific markers that can distinguish PCNSL from other CNS tumors in tissues. In a pilot study, we tested these newly identified markers in plasma.
RESULTS
The Methylation Outlier Detector program was used to identify markers in TCGA dataset of 48 diffuse large B-cell lymphoma (DLBCL) and 656 glioblastomas and lower-grade gliomas. Eight methylated markers clearly distinguished DLBCL from gliomas. Marker performance was verified (ROC-AUC of ≥ 0.989) in samples from several GEO datasets (95 PCNSL; 2112 other primary CNS tumors of 11 types). Next, we developed a novel, efficient assay called Tailed Amplicon Multiplexed-Methylation-Specific PCR (TAM-MSP), which uses two of the methylation markers, cg0504 and SCG3 triplexed with ACTB. FFPE tissue sections (25 cases each) of PCNSL and eight types of other primary CNS tumors were analyzed using TAM-MSP. TAM-MSP distinguished PCNSL from the other primary CNS tumors with 100% accuracy (AUC = 1.00, 95% CI 0.95-1.00, P < 0.001). The TAM-MSP assay also detected as few as 5 copies of fully methylated plasma DNA spiked into 0.5 ml of healthy plasma. In a pilot study of plasma from 15 PCNSL, 5 other CNS tumors and 6 healthy individuals, methylation in cg0504 and SCG3 was detectable in 3/15 PCNSL samples (20%).
CONCLUSION
The Methylation Outlier Detector program identified methylated markers that distinguish PCNSL from other CNS tumors with accuracy. The high level of accuracy achieved by these markers was validated in tissues by a novel method, TAM-MSP. These studies lay a strong foundation for a liquid biopsy-based test to detect PCNSL-specific circulating tumor DNA.
Identifiants
pubmed: 33952317
doi: 10.1186/s13148-021-01091-9
pii: 10.1186/s13148-021-01091-9
pmc: PMC8097855
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Subventions
Organisme : U.S. Department of Defense
ID : W81XWH1810482
Organisme : U.S. Department of Defense
ID : W81XWH-18-1-0018
Organisme : NIH HHS
ID : 1 R37 CA230400
Pays : United States
Organisme : NIH HHS
ID : 1 U01 CA230691
Pays : United States
Références
Neuro Oncol. 2014 Jan;16(1):140-6
pubmed: 24285547
PLoS Genet. 2016 Jul 18;12(7):e1006162
pubmed: 27428049
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Blood Adv. 2019 Dec 10;3(23):3953-3961
pubmed: 31805190
Genes Chromosomes Cancer. 2019 Jan;58(1):66-69
pubmed: 30284345
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5
pubmed: 18765795
Cancer Res. 2004 Jul 1;64(13):4442-52
pubmed: 15231653
Blood. 2019 Jan 31;133(5):436-445
pubmed: 30567753
Cancer Biol Ther. 2011 May 15;11(10):853-65
pubmed: 21383541
Int J Cancer. 2003 Dec 20;107(6):970-5
pubmed: 14601057
J Clin Oncol. 2006 Oct 10;24(29):4754-7
pubmed: 16966685
CNS Oncol. 2014 Jan;3(1):77-85
pubmed: 25054902
Cancer Res. 2014 Apr 15;74(8):2160-70
pubmed: 24737128
J Neurooncol. 2014 Apr;117(2):347-57
pubmed: 24519517
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
J Clin Oncol. 2006 Sep 10;24(26):4270-6
pubmed: 16963729
Int J Clin Exp Pathol. 2015 Jul 01;8(7):7798-808
pubmed: 26339344
Br J Cancer. 2011 Oct 25;105(9):1414-8
pubmed: 21915121
Surg Neurol Int. 2012;3(Suppl 4):S315-9
pubmed: 23230536
Int J Cancer. 2006 Nov 15;119(10):2487-91
pubmed: 16858686
Clin Cancer Res. 2019 Nov 1;25(21):6357-6367
pubmed: 31300453
Acta Neurochir (Wien). 2014 Aug;156(8):1441-50
pubmed: 24898761
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
BMC Cancer. 2009 Dec 21;9:455
pubmed: 20025734
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Neurooncol. 2013 Sep;114(3):275-9
pubmed: 23828278
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Cancer Genet Cytogenet. 2003 Apr 1;142(1):21-4
pubmed: 12660028
Oncotarget. 2015 Sep 29;6(29):27778-93
pubmed: 26356815
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9
pubmed: 26195750
Cancer Res. 2011 Oct 1;71(19):6195-207
pubmed: 21825015
NPJ Breast Cancer. 2020 Jan 31;6:3
pubmed: 32025567
Hematol Oncol. 2019 Jun;37 Suppl 1:15-18
pubmed: 31187523
Ann Hematol. 2011 Dec;90(12):1391-8
pubmed: 21479535
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214